G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
25 Julio 2024 - 10:15AM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, will host a webcast and conference call to provide a
financial and corporate update for the second quarter of 2024 on
Thursday August 8, 2024, at 8:30 a.m. ET.
To register for the event and receive a dial in number and
unique PIN to access the live conference call, please follow this
link to register online. While not required, it is recommended that
you join 10 minutes prior to the start of the event. A live and
archived webcast will be available on the Events &
Presentations page of the company’s website:
www.g1therapeutics.com. The webcast will be archived on the same
page for 90 days following the event.
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage oncology
biopharmaceutical company whose mission is to develop and deliver
next-generation therapies that improve the lives of those affected
by cancer, including the Company’s first commercial product,
COSELA® (trilaciclib). G1’s goal is to provide innovative
therapeutic advances for people living with cancer. G1 is based in
Research Triangle Park, N.C. For additional information,
please visit http://www.g1therapeutics.com and follow us on X
(formerly known as Twitter) @G1Therapeutics and LinkedIn.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and
the COSELA logo are trademarks of G1 Therapeutics, Inc.
G1 Therapeutics Contact:
Will RobertsCommunications OfficerVice President, Investor
Relations and Corporate Communications(919) 907-1944
wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
G1 Therapeutics (NASDAQ:GTHX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024